The center, located on the Buffalo Niagara Medical Campus in Buffalo, NY, was launched with the goal of creating a transitional science center leveraging infrastructure from AMRI’s partner institutes, and is part of a larger commitment by the state of New York with SUNY Polytechnic Institute.
"We are excited to launch a realigned and upgraded discovery service offering for our customers through our new center for global drug discovery in Buffalo," said Christopher Conway, Senior Vice President, Discovery and Development, AMRI.
"AMRI is the only North American based Discovery CRO with biology, pharmacology, HTS and chemistry located in one building, in the center of a hub of complimentary biotech, major medical and academic centers. This hub for drug discovery provides our customers and partners with the speed in decision-making and depth of collaboration need to accelerate speed of data and maximize results."
Other partners in the project include the University at Buffalo School of Medicine, University at Buffalo Clinical and Translational Research Center, Buffalo General Hospital, Jacobs Institute, Roswell Park Cancer Institute, and the Hauptman Woodward Institute.
According to Rory Curtis, Vice President, Discovery Biology and Pharmacology, and Site Head of AMRI Buffalo, “The ultimate aim of this site is to provide a suite of discovery services, from assay development and HTS to medicinal chemistry and in vitro pharmacology, that will reduce data cycle times in order to improve the value of our customers' discovery programs, as well as offer ease-of-communication with project teams and functional groups."
AMRI is a founding member of the Buffalo Medical Innovation and Commercialization Hub (BMIC). By combining the expertise of academic and industrial partners the hub will offer opportunities for collaborations to develop new approaches to discover life-saving therapies.